593 related articles for article (PubMed ID: 27989769)
1. Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.
Liau BB; Sievers C; Donohue LK; Gillespie SM; Flavahan WA; Miller TE; Venteicher AS; Hebert CH; Carey CD; Rodig SJ; Shareef SJ; Najm FJ; van Galen P; Wakimoto H; Cahill DP; Rich JN; Aster JC; Suvà ML; Patel AP; Bernstein BE
Cell Stem Cell; 2017 Feb; 20(2):233-246.e7. PubMed ID: 27989769
[TBL] [Abstract][Full Text] [Related]
2. Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
Staberg M; Rasmussen RD; Michaelsen SR; Pedersen H; Jensen KE; Villingshøj M; Skjoth-Rasmussen J; Brennum J; Vitting-Seerup K; Poulsen HS; Hamerlik P
Mol Oncol; 2018 Mar; 12(3):406-420. PubMed ID: 29360266
[TBL] [Abstract][Full Text] [Related]
3. The role of histone H3 lysine demethylases in glioblastoma.
Young D; Guha C; Sidoli S
Cancer Metastasis Rev; 2023 Jun; 42(2):445-454. PubMed ID: 37286866
[TBL] [Abstract][Full Text] [Related]
4. Glioblastoma initiating cells are sensitive to histone demethylase inhibition due to epigenetic deregulation.
Mallm JP; Windisch P; Biran A; Gal Z; Schumacher S; Glass R; Herold-Mende C; Meshorer E; Barbus M; Rippe K
Int J Cancer; 2020 Mar; 146(5):1281-1292. PubMed ID: 31456217
[TBL] [Abstract][Full Text] [Related]
5. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
6. Structure of the Arabidopsis JMJ14-H3K4me3 Complex Provides Insight into the Substrate Specificity of KDM5 Subfamily Histone Demethylases.
Yang Z; Qiu Q; Chen W; Jia B; Chen X; Hu H; He K; Deng X; Li S; Tao WA; Cao X; Du J
Plant Cell; 2018 Jan; 30(1):167-177. PubMed ID: 29233856
[TBL] [Abstract][Full Text] [Related]
7. Comparative analyses identify molecular signature of MRI-classified SVZ-associated glioblastoma.
Lin CA; Rhodes CT; Lin C; Phillips JJ; Berger MS
Cell Cycle; 2017 Apr; 16(8):765-775. PubMed ID: 28278055
[TBL] [Abstract][Full Text] [Related]
8. A curcumin derivative hydrazinobenzoylcurcumin suppresses stem-like features of glioblastoma cells by targeting Ca
Shin HJ; Lee S; Jung HJ
J Cell Biochem; 2019 Apr; 120(4):6741-6752. PubMed ID: 30390339
[TBL] [Abstract][Full Text] [Related]
9. Histone demethylase lysine demethylase 5B in development and cancer.
Han M; Xu W; Cheng P; Jin H; Wang X
Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
[TBL] [Abstract][Full Text] [Related]
10. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway.
Garner JM; Fan M; Yang CH; Du Z; Sims M; Davidoff AM; Pfeffer LM
J Biol Chem; 2013 Sep; 288(36):26167-26176. PubMed ID: 23902772
[TBL] [Abstract][Full Text] [Related]
11. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
12. Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism.
Phillips E; Lang V; Bohlen J; Bethke F; Puccio L; Tichy D; Herold-Mende C; Hielscher T; Lichter P; Goidts V
Int J Cancer; 2016 Oct; 139(8):1776-87. PubMed ID: 27299852
[TBL] [Abstract][Full Text] [Related]
13. Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
Ramadoss S; Guo G; Wang CY
Oncogene; 2017 Jan; 36(1):47-59. PubMed ID: 27270439
[TBL] [Abstract][Full Text] [Related]
14. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M
Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863
[TBL] [Abstract][Full Text] [Related]
15. Vitamin C-dependent lysine demethylase 6 (KDM6)-mediated demethylation promotes a chromatin state that supports the endothelial-to-hematopoietic transition.
Zhang T; Huang K; Zhu Y; Wang T; Shan Y; Long B; Li Y; Chen Q; Wang P; Zhao S; Li D; Wu C; Kang B; Gu J; Mai Y; Wang Q; Li J; Zhang Y; Liang Z; Guo L; Wu F; Su S; Wang J; Gao M; Zhong X; Liao B; Chen J; Zhang X; Shu X; Pei D; Nie J; Pan G
J Biol Chem; 2019 Sep; 294(37):13657-13670. PubMed ID: 31341023
[TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
[TBL] [Abstract][Full Text] [Related]
17. Lysine Demethylase KDM6A in Differentiation, Development, and Cancer.
Tran N; Broun A; Ge K
Mol Cell Biol; 2020 Sep; 40(20):. PubMed ID: 32817139
[TBL] [Abstract][Full Text] [Related]
18. Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization.
Ene CI; Edwards L; Riddick G; Baysan M; Woolard K; Kotliarova S; Lai C; Belova G; Cam M; Walling J; Zhou M; Stevenson H; Kim HS; Killian K; Veenstra T; Bailey R; Song H; Zhang W; Fine HA
PLoS One; 2012; 7(12):e51407. PubMed ID: 23236496
[TBL] [Abstract][Full Text] [Related]
19. Glioma Stem Cell-Specific Superenhancer Promotes Polyunsaturated Fatty-Acid Synthesis to Support EGFR Signaling.
Gimple RC; Kidwell RL; Kim LJY; Sun T; Gromovsky AD; Wu Q; Wolf M; Lv D; Bhargava S; Jiang L; Prager BC; Wang X; Ye Q; Zhu Z; Zhang G; Dong Z; Zhao L; Lee D; Bi J; Sloan AE; Mischel PS; Brown JM; Cang H; Huan T; Mack SC; Xie Q; Rich JN
Cancer Discov; 2019 Sep; 9(9):1248-1267. PubMed ID: 31201181
[TBL] [Abstract][Full Text] [Related]
20. JIB-04, a Pan-Inhibitor of Histone Demethylases, Targets Histone-Lysine-Demethylase-Dependent AKT Pathway, Leading to Cell Cycle Arrest and Inhibition of Cancer Stem-Like Cell Properties in Hepatocellular Carcinoma Cells.
Lee J; Kim JS; Cho HI; Jo SR; Jang YK
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
